ArticleFrontiers in immunology2018
Kallikrein-Kinin System Suppresses Type I Interferon Responses: A Novel Pathway of Interferon Regulation.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Neuropsychiatric systemic lupus erythematosus - current and novel treatments.Current opinion in rheumatology · 2026Review
- The immunomodulatory potential of bradykinin signaling in autoimmune conditions.Frontiers in immunology · 2026Review
- Paneth cells inhibit intestinal stem cell proliferation through the bone morphogenic protein 7 pathway under rotavirus-mediated intestinal injury.World journal of gastroenterology · 2025Article
- Tissue Kallikrein-1 Suppresses Type I Interferon Responses and Reduces Depressive-Like Behavior in the MRL/lpr Lupus-Prone Mouse Model.International journal of molecular sciences · 2024Article
- Delayed plasma kallikrein inhibition fosters post-stroke recovery by reducing thrombo-inflammation.Journal of neuroinflammation · 2024Article
- Lupus autoantibodies initiate neuroinflammation sustained by continuous HMGB1:RAGE signaling and reversed by increased LAIR-1 expression.Nature immunology · 2024Article
- Plasma and urine proteomics and gut microbiota analysis reveal potential factors affecting COVID-19 vaccination response.iScience · 2024Article
- Vascular Inflammation in Mouse Models of Systemic Lupus Erythematosus.Frontiers in cardiovascular medicine · 2022Article
- COVID-19 and hereditary angioedema: Incidence, outcomes, and mechanistic implications.Allergy and asthma proceedings · 2021Article
- Contact System Activation in Plasma from Dengue Patients Might Harness Endothelial Virus Replication through the Signaling of Bradykinin Receptors.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Siglec-H-Deficient Mice Show Enhanced Type I IFN Responses, but Do Not Develop Autoimmunity After Influenza or LCMV Infections.Frontiers in immunology · 2021Article
- Kallikrein 13 serves as a priming protease during infection by the human coronavirus HKU1.Science signaling · 2020Article
- SARS-CoV-2 and interferon blockade.Molecular medicine (Cambridge, Mass.) · 2020Review
- The renin-angiotensin system: An integrated view of lung disease and coagulopathy in COVID-19 and therapeutic implications.The Journal of experimental medicine · 2020Article
- BBritish journal of pharmacology · 2020Article
- The Emerging Role of Renal Tubular Epithelial Cells in the Immunological Pathophysiology of Lupus Nephritis.Frontiers in immunology · 2020Review
- Centrally Acting Angiotensin-Converting Enzyme Inhibitor Suppresses Type I Interferon Responses and Decreases Inflammation in the Periphery and the CNS in Lupus-Prone Mice.Frontiers in immunology · 2020Article
- COVID-19 Usurps Host Regulatory Networks.Frontiers in pharmacology · 2020Review
- Cognitive Dysfunction in Systemic Lupus Erythematosus: A Case for Initiating Trials.Arthritis & rheumatology (Hoboken, N.J.) · 2019Review
- Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors.The Journal of experimental medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
The Kallikrein-Kinin System (KKS), comprised of kallikreins (klks), bradykinins (BKs) angiotensin-converting enzyme (ACE), and many other molecules, regulates a number of physiological processes, including inflammation, coagulation, angiogenesis, and control of blood pressure. In this report, we show that KKS regulates Type I IFN responses, thought to be important in lupus pathogenesis. We used CpG (TLR9 ligand), R848 (TLR7 ligand), or recombinant IFN-α to induce interferon-stimulated genes (ISGs) and proteins, and observed that this response was markedly diminished by BKs, klk1 (tissue kallikrein), or captopril (an ACE inhibitor). BKs significantly decreased the ISGs induced by TLRs
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.